CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 192 enrolled
Drug / intervention
INO-4700 +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04588428
NCT04588428Phase 2Completed
CompareCT.gov

Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers

Inovio Pharmaceuticals·interventional·Posted Oct 19, 2020·Updated Jan 22, 2026

In Brief

A Phase 2 clinical trial evaluating INO-4700, Placebo, and 1 other intervention for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Completed, enrolled 192 participants across 6 sites in 3 countries.

Detailed Summary

The purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy adult volunteers for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. This study was divided into 2 parts: Part 1- dose finding stage and Part 2- dose expansion stage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMiddle East Respiratory Syndrome Coronavirus (MERS-CoV)
CountriesJordan, Kenya, Lebanon
CollaboratorsCoalition for Epidemic Preparedness Innovations

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedOct 19, 2020
Enrollment StartJun 21, 2021
Primary CompletionJan 19, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.7 years ago

Interventions

INO-4700drug

INO-4700 was administered ID.

Placebodrug

Sterile saline sodium citrate (SSC) buffer (SSC-0001) was administered ID.

CELLECTRA™ 2000device

EP using the CELLECTRA™ 2000 device was administered following ID drug administration

INO-4700drug

INO-4700

CELLECTRA™ 2000device

CELLECTRA™ 2000